Clinical Trial Update: Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SPP100 (aliskiren) 150 mg to placebo and to losartan 50 mg in adults with mild to moderate essential hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Losartan (losartan)
• SPP100

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED